CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors.

ABSTRACT:

Background

While cancer vaccines have demonstrated promising clinical potential, their therapeutic efficacy against advanced tumors remains suboptimal, highlighting the critical need to elucidate resistance mechanisms and develop targeted solutions. We previously developed a stimulator of interferon genes (STING)-activating PC7A nanovaccine that elicits strong antitumor efficacy in multiple tumor models. In this study, we systematically investigated the mechanisms mediating nanovaccine resistance and provided targeting approaches to overcome this therapeutic barrier.

Methods

Vaccine efficacy at early stage and advanced-stage tumors was investigated in the B16-OVA melanoma model and TC-1 human papillomavirus-induced cancer model, with tumor microenvironment being comprehensiv

SUBMITTER: Wang X 

PROVIDER: S-EPMC12815194 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature